FrancophonIA/ELRC3.0 huggingface dataset:
English: 0.5 mg Capsule, hard
Slovenian: 0,5 mg Kapsula, trda
English: Xagrid
Slovenian: Ovojnina
English: Invented name Strength Pharmaceutical Form Route of administration Packaging Package size
Slovenian: Farmacevtska oblika Pot uporabe
English: Bottle (HDPE) 100 capsules
Slovenian: 100 kapsul
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ifirmacombi on 4 March 2011.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Ifirmacombi, veljavno po vsej Evropski uniji, izdala 4. marca 2011.
English: This means that Ifirmacombi is similar to a ‘reference medicine' already authorised in the European Union (EU) called CoAprovel.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu CoAprovel.
English: What are the benefits and risks of Ifirmacombi?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Ifirmacombi?
English: It is available as tablets (150 mg irbesartan and 12.5 mg hydrochlorothiazide; 300 mg irbesartan and 25 mg hydrochlorothiazide; 300 mg irbesartan and 12.5 mg hydrochlorothiazide).
Slovenian: Na voljo je v obliki tablet (150 mg irbesartana in 12,5 mg hidrokolorotiazida; 300 mg irbesartana in 25 mg hidrokolorotiazida; 300 mg irbesartana in 12,5 mg hidroklorotiazida).
English: The full EPAR for Ifirmacombi can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ifirmacombi je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Irbesartan/hydrochlorothiazide
Slovenian: Ifirmacombi irbesartan/hidroklorotiazid
English: For more information about treatment with Ifirmacombi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Ifirmacombi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Ifirmacombi.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ifirmacombi.
English: Other information about Ifirmacombi
Slovenian: Druge informacije o zdravilu Ifirmacombi
English: Because Ifirmacombi is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Ifirmacombi generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ifirmacombi.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Ifirmacombi, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Ifirmacombi is a ‘generic medicine'.
Slovenian: Zdravilo Ifirmacombi je „generično zdravilo“.
English: Why has Ifirmacombi been approved?
Slovenian: Zakaj je bilo zdravilo Ifirmacombi odobreno?
English: The dose of Ifirmacombi to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before.
Slovenian: Odmerek zdravila Ifirmacombi, ki ga bolnik uporabi, je odvisen od odmerka irbesartana ali hidroklorotiazida, ki ga je bolnik jemal prej.
English: The Committee recommended that Ifirmacombi be given marketing authorisation.
Slovenian: Priporočil je, da se za zdravilo Ifirmacombi izda dovoljenje za promet.
English: Ifirmacombi is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone.
Slovenian: Zdravilo Ifirmacombi se uporablja pri odraslih bolnikih, ki imajo esencialno hipertenzijo (visok krvni tlak), ki je ni mogoče ustrezno uravnavati samo z irbesartanom ali hidroklorotiazidom.
English: The CHMP concluded that, in accordance with EU requirements, Ifirmacombi has been shown to have comparable quality and to be bioequivalent to CoAprovel.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Ifirmacombi primerljivo raven kakovosti kot zdravilo CoAprovel ter da mu je biološko enakovredno.
English: Because Ifirmacombi is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, CoAprovel.
Slovenian: Ker je zdravilo Ifirmacombi generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu CoAprovel.
English: The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone.
Slovenian: Kombinacija obeh zdravilnih učinkovin daje pri zniževanju krvnega tlaka boljše rezultate kot posamezni učinkovini, uporabljeni kot samostojni zdravili.
English: Ifirmacombi may be added to other treatments for hypertension.
Slovenian: Zdravilo Ifirmacombi je mogoče uvesti sočasno z drugimi načini zdravljenja hipertenzije.
English: Ifirmacombi is a medicine that contains two active substances, irbesartan and hydrochlorothiazide.
Slovenian: Ifirmacombi je zdravilo, ki vsebuje dve zdravilni učinkovini, irbesartan in hidroklorotiazid.
English: What is Ifirmacombi?
Slovenian: Kaj je zdravilo Ifirmacombi?
English: What is Ifirmacombi used for?
Slovenian: Za kaj se zdravilo Ifirmacombi uporablja?
English: How has Ifirmacombi been studied?
Slovenian: Kako je bilo zdravilo Ifirmacombi raziskano?
English: Ifirmacombi contains two active substances, irbesartan and hydrochlorothiazide.
Slovenian: Zdravilo Ifirmacombi vsebuje dve zdravilni učinkovini, irbesartan in hidroklorotiazid.
English: Therefore, the CHMP's view was that, as for CoAprovel, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da koristi zdravila Ifirmacombi, tako kot pri zdravilu CoAprovel, odtehtajo znana tveganja.
English: How is Ifirmacombi used?
Slovenian: Kako se zdravilo Ifirmacombi uporablja?
English: How does Ifirmacombi work?
Slovenian: Kako zdravilo Ifirmacombi deluje?
English: The company will also carry out studies to further characterise this risk.
Slovenian: Družba bo izvedla tudi študije za dodatno opredelitev tega tveganja.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rienso on 15 June 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Rienso, veljavno po vsej Evropski uniji, izdala 15. junija 2012.
English: Rienso ferumoxytol
Slovenian: Rienso ferumoksitol
English: The full EPAR for Rienso can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila Rienso je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Depending on the severity of the anaemia and the patient's body weight, a second infusion may be given two to eight days after the first dose.
Slovenian: Glede na resnost anemije in bolnikovo telesno maso lahko ta dva do osem dni po prvem odmerku prejme drugo infuzijo.
English: The main measure of effectiveness was how much haemoglobin levels (measured in grams per decilitre, g/dl) rose after five weeks.
Slovenian: Glavno merilo učinkovitosti je bila rast ravni hemoglobina (izmerjenih v gramih na deciliter, g/dl) po petih tednih.
English: This is a summary of the European public assessment report (EPAR) for Rienso.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rienso.
English: What measures are being taken to ensure the safe and effective use of Rienso?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rienso?
English: In studies with Rienso, side effects were seen in 7.9% of patients taking the medicine, of which 0.2% were considered serious.
Slovenian: V študijah zdravila Rienso so pri 7,9 % bolnikov opazili neželene učinke, od katerih jih je bilo 0,2 % ocenjenih kot resnih.
English: Serious cases of hypersensitivity (allergic reaction) or hypotension were uncommon and were seen in 0.2% of patients.
Slovenian: Pojavi resnih preobčutljivostnih (alergijskih) reakcij ali hipotenzije so bili redki in opaženi pri 0,2 % bolnikov.
English: In all three studies, patients taking Rienso had higher average increases in haemoglobin: 1.2 g/dl versus 0.5 g/dl; 0.8 g/dl versus 0.2 g/dl; and 1.0 g/dl versus 0.5 g/dl.
Slovenian: 1,2 g/dl v primerjavi z 0,5 g/dl; 0,8 g/dl v primerjavi z 0,2 g/dl in 1,0 g/dl v primerjavi z 0,5 g/dl.
English: The CHMP decided that Rienso's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Rienso večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Other information about Rienso
Slovenian: Druge informacije o zdravilu Rienso
English: For more information about treatment with Rienso, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Rienso preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Rienso is given as an infusion into a vein lasting at least 15 minutes.
Slovenian: Zdravilo Rienso se daje kot infuzija v veno v trajanju vsaj 15 minut.
English: The increase in haemoglobin seen in the main studies was considered by the CHMP to be a valuable improvement and comparable to what is obtained with standard intravenous iron preparations.
Slovenian: Odbor je dvig ravni hemoglobina, opažen v glavnih študijah, ocenil kot pomembno izboljšanje, ki je primerljivo z rezultati, doseženimi z običajnimi intravenskimi železovimi pripravki.
English: With the iron stores replenished, the body can produce more haemoglobin, which will help correct the anaemia.
Slovenian: Ko se zaloge železa obnovijo, lahko telo tvori več hemoglobina, kar pomaga odpraviti anemijo.
English: A risk management plan has been developed to ensure that Rienso is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Rienso je bil pripravljen načrt obvladovanja tveganj.
English: What benefit has Rienso shown during the studies?
Slovenian: Kakšne koristi je zdravilo Rienso izkazalo med študijami?
English: The doctor should ensure that the patient is observed for adverse reactions for at least 30 minutes following the infusion.
Slovenian: Zaradi neželenih učinkov mora zdravnik zagotoviti, da se bolnika opazuje še vsaj 30 minut po vsakem infundiranju.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rienso.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Patients should have their blood and iron levels tested after at least one month following treatment.
Slovenian: Vsaj en mesec po zdravljenju je treba pri bolnikih opraviti preiskave krvi in ravni železa.
English: Iron deficiency is a common cause of anaemia in patients with long-term kidney disease and is itself caused by many factors including the poor absorption of dietary iron from food.
Slovenian: Pomanjkanje železa je običajen vzrok za anemijo pri bolnikih z dolgotrajnim obolenjem ledvic, povzročijo pa ga številni dejavniki, med drugim slaba absorpcija železa iz živil.
English: The most frequently reported side effects were symptoms affecting the gut (diarrhoea, constipation, nausea and vomiting), headache, dizziness and hypotension (low blood pressure), all occurring in less than 2.5% of patients.
Slovenian: Najpogosteje zabeleženi neželeni učinki so simptomi, povezani s črevesjem (driska, zaprtje, slabost in bruhanje), glavobol, omotica in hipotenzija (nizek krvni tlak).
English: Rienso is used to treat anaemia (low levels of red blood cells or haemoglobin) caused by a deficiency of iron in patients with chronic kidney disease (long-term, progressive decrease in the ability of the kidneys to work properly).
Slovenian: Zdravilo Rienso se uporablja za zdravljenje anemije (nizke ravni rdečih krvničk ali hemoglobina), ki ga povzroča pomanjkanje železa pri bolnikih s kroničnim obolenjem ledvic (dolgotrajnim, postopnim zmanjšanjem sposobnosti pravilnega delovanja ledvic).
English: Rienso should only be given when healthcare professionals trained to manage anaphylactic (severe allergic) reactions and full resuscitation facilities are available.
Slovenian: Zdravilo Rienso se daje samo ob navzočnosti zdravstvenih delavcev, izkušenih v obravnavi anafilaktičnih (hudih alergijskih) reakcij, in kadar je na voljo popolna oprema za oživljanje.
English: Rienso must not be used in people with a history of drug allergy, including allergy to ferumoxytol or any other iron preparation.
Slovenian: Zdravila Rienso ne smejo uporabljati osebe z anamnezo alergije na zdravilo, vključno z alergijo na ferumoksitol ali kateri koli drug železov pripravek.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rienso, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: It must not be used in patients with evidence of excess iron in the body or in patients whose anaemia is not caused by iron deficiency.
Slovenian: Ne sme se uporabiti pri ljudeh, ki izkazujejo presežek železa v krvi ali katerih anemija ni posledica pomanjkanja železa.
English: To maintain normal haemoglobin levels, patients may be re-treated with Rienso if they are confirmed to be lacking iron.
Slovenian: Za vzdrževanje običajnih ravni hemoglobina se lahko zdravljenje z zdravilom Rienso ponovi, če se pri bolniku ugotovi ponovno pomanjkanje železa.
English: What is the risk associated with Rienso?
Slovenian: Kakšna tveganja so povezana z zdravilom Rienso?
English: In addition, the company that market Rienso will provide educational material to patients and doctors expected to use Rienso, with information on the risk of allergic reactions.
Slovenian: Poleg tega bo družba, ki trži zdravilo Rienso, bolnikom in zdravnikom, ki naj bi uporabljali to zdravilo, priskrbela izobraževalno gradivo, v katerem bodo pojasnjena tveganja za pojav alergijskih reakcij.
English: For the full list of all side effects reported with Rienso, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rienso, glejte navodilo za uporabo.
English: Why has Rienso been approved?
Slovenian: Zakaj je bilo zdravilo Rienso odobreno?
English: Rienso is an iron preparation that contains the active substance ferumoxytol.
Slovenian: Zdravilo Rienso je železov pripravek, ki vsebuje zdravilno učinkovino ferumoksitol.
English: The active substance in Rienso, ferumoxytol, is an iron-containing compound.
Slovenian: Zdravilna učinkovina v zdravilu Rienso, ferumoksitol, je spojina, ki vsebuje železo.
English: Rienso was shown to be superior to iron taken by mouth in treating iron deficiency anaemia in patients with chronic kidney disease.
Slovenian: Zdravilo Rienso se je izkazalo za boljše v primerjavi s peroralnimi železovimi pripravki za zdravljenje anemije, ki je posledica pomanjkanja železa pri bolnikih s kroničnim ledvičnim obolenjem.
English: Rienso was more effective at increasing haemoglobin levels than the iron treatment taken by mouth.
Slovenian: Zdravilo Rienso je bilo pri zviševanju ravni hemoglobina učinkovitejše od peroralnih zdravil.
English: Three main studies involving 838 chronic kidney disease patients with iron deficiency anaemia have been carried out to compare Rienso with an iron treatment taken by mouth.
Slovenian: Za primerjavo zdravila Rienso z drugo vrsto peroralnega zdravljenja so bile opravljene tri glavne študije, v katerih je sodelovalo 838 bolnikov s kroničnim ledvičnim obolenjem z anemijo zaradi pomanjkanja železa.
English: What is Rienso used for?
Slovenian: Za kaj se zdravilo Rienso uporablja?
English: What is Rienso?
Slovenian: Kaj je zdravilo Rienso?
English: How has Rienso been studied?
Slovenian: Kako je bilo zdravilo Rienso raziskano?
English: How does Rienso work?
Slovenian: Kako zdravilo Rienso deluje?
English: When injected into the blood, it is taken up by cells in the liver, spleen and the bone marrow, at which point the iron is released from the compound and replaces the body's depleted iron stores.
Slovenian: Ko se ferumoksitol injicira v kri, se veže na celice v jetrih, vranici in kostnem mozgu.
English: How is Rienso used?
Slovenian: Kako se zdravilo Rienso uporablja?
English: 26 March 2010
Slovenian: 26. marec 2010
English: The final opinion was converted into a Decision by the European Commission on 26 March 2010.
Slovenian: Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 26. marca 2010.
English: The Rapporteur and Co-Rapporteur appointed were: Dr A. Holm and Dr B. Kolar, respectively.
Slovenian: Poročevalec in soporočevalec sta bila: dr. A. Holm oziroma dr. B. Kolar.
English: The Decentralised Procedure FR/V/195/01/DC started on 29 February 2008.
Slovenian: Decentralizirani postopek FR/V/195/01/DC se je začel 29. februarja 2008.
English: The application was submitted in the framework of Article 32 of Directive 2001/82/EC, where the Reference Member State was France and the Concerned Member States were Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Spain and United Kingdom.
Slovenian: Vloga je bila predložena v skladu s členom 32 Direktive 2001/82/ES, kakor je bila spremenjena, pri čemer je bila Francija referenčna država članica, Avstrija, Belgija, Bolgarija, Ciper, Češka republika, Danska, Estonija, Nemčija, Grčija, Madžarska, Irska, Italija, Latvija, Litva, Luksemburg, Malta, Nizozemska, Poljska, Portugalska, Romunija, Slovaška, Španija in Združeno kraljestvo pa zadevne države članice.
English: Oral explanations were given on 8 December 2009.
Slovenian: Ustna pojasnila so bila podana 8. decembra 2009.
English: The referral procedure started on 12 May 2009.
Slovenian: Napotitveni postopek se je začel 12. maja 2009.
English: Written explanations were provided by the Applicant on 18 August 2009.
Slovenian: Pisna pojasnila je predlagatelj predložil 18. avgusta 2009.
English: Toltrazuril is a triazinon derivative administered orally to piglets for the prevention of clinical signs of coccidiosis in neonatal piglets on farms with a confirmed history of coccidiosis caused by Isospora suis.
Slovenian: Toltrazuril je derivat triazinona, ki se daje peroralno pujskom, za preprečevanje kliničnih znakov poporodne kokcidioze pri pujskih na kmetijah, na katerih je bila v preteklosti že potrjena kokcidioza, ki jo povzroča Isospora suis.
English: On 6 May 2009 France, referred the matter to the Agency under Article 33(4) of Directive 2001/82/EC, due to concerns, raised by Germany, Spain, Portugal, Poland and the United Kingdom, that the marketing authorisation of CEVAZURIL 50 mg/ml oral suspension for piglets may present a potential serious risk to the environment.
Slovenian: Francija je 6. maja 2009 v skladu s členom 33(4) Direktive 2001/82/ES zadevo napotila na agencijo EMA zaradi zadržkov, ki so jih izpostavile Nemčija, Španija, Portugalska, Poljska in Združeno kraljestvo, in sicer, da utegne dovoljenje za promet z zdravilom CEVAZURIL 50 mg/ml peroralna suspenzija za pujske predstavljati možno resno tveganje za okolje.
English: Based on the evaluation of the rapporteur's assessment of the currently available data, on 9 December 2009 the CVMP considered that the objections raised during the decentralised procedure should not prevent the granting of a Marketing Authorisation for CEVAZURIL 50 mg/ml oral suspension for piglets.
Slovenian: Na podlagi ocene poročevalčevega vrednotenja trenutno razpoložljivih podatkov je 9. decembra 2009 Odbor za zdravila za uporabo v veterinarski medicini (CVMP) menil, da zadržki, izpostavljeni med decentraliziranim postopkom, ne bi smeli preprečiti izdaje dovoljenja za promet z zdravilom CEVAZURIL 50 mg/ml peroralna suspenzija za pujske.
English: The Applicant, Ceva Santé Animale, submitted an application for a decentralised procedure for CEVAZURIL 50 mg/ml oral suspension for piglets.
Slovenian: Predlagatelj Ceva Santé Animale je predložil vlogo za pridobitev dovoljenja po decentraliziranem postopku za zdravilo CEVAZURIL 50 mg/ml peroralna raztopina za pujske.
English: referral for CEVAZURIL 50 mg/ml oral suspension for piglets
Slovenian: Mnenje v zvezi z napotitvijo v skladu s členom 33(4)1 za zdravilo CEVAZURIL 50 mg/ml peroralna suspenzija za pujske
English: On this basis, no further revisions were warranted.
Slovenian: Na podlagi tega niso bile potrebne nobene druge spremembe.
English: • The committee considered the referral under Article 30 of Directive 2001/83/EC
Slovenian: • Odbor je obravnaval napotitev v skladu s členom 30 Direktive 2001/83/ES;
English: Readability testing has been performed at a national level.
Slovenian: Opravljeno je bilo tudi preverjanje berljivosti na nacionalni ravni.
English: Other indications
Slovenian: Druge indikacije
English: Lyme Borreliosis
Slovenian: Lymska borelioza
English: Section 4.7 - Effects on ability to drive and use machines
Slovenian: Poglavje 4.7 - Vpliv na sposobnosti vožnje in upravljanja strojev
English: Overall summary of the scientific evaluation of Rocephin and associated names (see Annex I)
Slovenian: Splošni povzetek znanstvenega vrednotenja zdravila Rocephin in povezanih imen (glejte Prilogo I)
English: Gonorrhoea, gonococcal arthritis, gonococcal eye infection
Slovenian: Gonoreja, gonokokni artritis, gonokokna okužba očesa
English: Information on absorption, distribution, metabolism and elimination has been provided.
Slovenian: Predloženi so bili podatki o absorpciji, porazdelitvi, presnovi in izločanju.
English: Infections with impaired defence mechanisms
Slovenian: Okužbe z oslabljenimi obrambnimi mehanizmi
English: The half-life increases in the elderly, and in older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.
Slovenian: Razpolovni čas se pri starejših podaljša, pri čemer je pri osebah, starejših od 75 let, povprečen razpolovni čas izločanja običajno dva- do trikrat daljši kot pri mlajših odraslih.
English: The elimination half-life of total ceftriaxone in adults is about 8 hours.
Slovenian: Razpolovni čas izločanja celotnega ceftriaksona pri odraslih je približno osem ur.
English: Dose recommendations have been listed in tabular format according to dosage schedules for each indication for: Adults and children over 12 years of age (≥ 50 kg), Neonates, infants and children 15 days to 12 years of age (< 50 kg) and Neonates 0-14 days.
Slovenian: Priporočila za odmerjanje so navedena v preglednici glede na režime odmerjanja pri posamezni indikaciji za: odrasle in otroke, starejše od 12 let (≥ 50 kg), novorojenčke, dojenčke in otroke, stare od 15 dni do 12 let (< 50 kg), ter novorojenčke, stare od 0 do 14 dni.
English: It is stated that the treatment of overdose should be symptomatic.
Slovenian: Navedeno je tudi, da mora biti zdravljenje prevelikega odmerjanja simptomatsko.